Catestatin exerts direct protective effects on rat cardiomyocytes undergoing ischemia/ reperfusion by stimulating PI3K-Akt-GSK3β pathway and preserving mitochondrial membrane potential

PLoS ONE

Volumn 10, Issue 3, 2015, Pages

  Bassino, Eleonora ^a   Fornero, Sara ^a   Gallo, Maria Pia ^a   Gallina, Clara ^a   Femminò, Saveria ^a   Levi, Renzo ^a   Tota, Bruno ^b,c   Alloatti, Giuseppe ^a,c  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF CALABRIA   (Italy)

^c National Institute for Cardiovascular Research   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CATESTATIN; CYCLIC GMP; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GLYCOGEN SYNTHASE KINASE 3BETA; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOLAMBAN; PROTEIN KINASE B; CHROMOGRANIN A; CHROMOGRANIN A (344-364); GLYCOGEN SYNTHASE KINASE 3; PEPTIDE FRAGMENT;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL ISOLATION; CELL PROTECTION; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; HEART MUSCLE CELL; IMMUNOFLUORESCENCE; ISCHEMIA; MITOCHONDRIAL MEMBRANE POTENTIAL; NONHUMAN; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; RAT; REPERFUSION INJURY; SIGNAL TRANSDUCTION; YOUNG ADULT; ANIMAL; CARDIAC MUSCLE CELL; CELL SURVIVAL; DRUG EFFECTS; METABOLISM; MYOCARDIAL REPERFUSION INJURY; PATHOLOGY;

RATTUS;

ANIMALS; CELL SURVIVAL; CHROMOGRANIN A; GLYCOGEN SYNTHASE KINASE 3; MEMBRANE POTENTIAL, MITOCHONDRIAL; MYOCARDIAL REPERFUSION INJURY; MYOCYTES, CARDIAC; PEPTIDE FRAGMENTS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RATS; SIGNAL TRANSDUCTION;

EID: 84925014352     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0119790     Document Type: Article

References (35)

1. Helle KB, Corti A, Metz-Boutigue MH, Tota B. The endocrine role for chromogranin A: a prohormone for peptides with regulatory properties. Cell Mol Life Sci. 2007; 64: 2863-2886. PMID: 17717629
2. Helle KB. The chromogranin A-derived peptides vasostatin-1 and catestatin as regulatory peptides for cardiovascular functions. Cardiovasc Res. 2010; 85: 9-16. doi: 10.1093/cvr/cvp266 PMID: 19640932
3. Fornero A, Bassino E, Gallo MP, Ramella R, Levi R, Alloatti G. Endothelium Dependent Cardiovascular Effects of the Chromogranin A-Derived Peptides Vasostatin-1 and Catestatin. Curr Med Chem. 2012; 19: 4059-4067. PMID: 22834796
4. Tota B, Angelone T, Mazza R, Cerra MC. The chromogranin A-derived vasostatins: new players in the endocrine heart. Curr Med Chem. 2008; 15: 1444-1451. PMID: 18537621
5. Pieroni M, Corti A, Tota B, Curnis F, Angelone T, Colombo B, et al. Myocardial production of chromogranin A in human heart: a new regulatory peptide of cardiac function. Eur Heart J. 2007; 28: 1117-1127. PMID: 17389654
6. Willis M, Leitner I, Jellinger KA, Marksteiner J. Chromogranin peptides in brain diseases. J Neural Transm. 2011; 118: 727-735. doi: 10.1007/s00702-011-0648-z PMID: 21533607
7. Ceconi C, Ferrari R, Bachetti T, Opasich C, Volterrani M, Colombo B, et al. Chromogranin A in heart failure; a novel neurohumoral factor and a predictor for mortality. Eur Heart J. 2002; 23: 967-974. PMID: 12069452
8. Fung MM, Salem RM, Mehtani P, Thomas B, Lu CF, Perez B, et al. Direct vasoactive effects of the chromogranin A (CHGA) peptide catestatin in humans in vivo. Clin Exp Hypertens. 2010; 32: 278-287. doi: 10.3109/10641960903265246 PMID: 20662728
9. Angelone T, Quintieri AM, Brar BK, Limchaiyawat PT, Tota B, Mahata SK, et al. The antihypertensive chromogranin a peptide catestatin acts as a novel endocrine/paracrine modulator of cardiac inotropism and lusitropism. Endocrinology. 2008; 149: 4780-4793. doi: 10.1210/en.2008-0318 PMID: 18535098
10. Bassino E, Fornero S, Gallo MP, Ramella R, Mahata SK, Tota B, et al. A novel catestatin-induced antiadrenergic mechanism triggered by the endothelial PI3K-eNOS pathway in the myocardium. Cardiovasc Res. 2011; 91: 617-624. doi: 10.1093/cvr/cvr129 PMID: 21543385
11. Angelone T, Quintieri AM, Pasqua T, Tota B, Mahata SK, Cerra MC. Phosphodiesterase type-2 and NO-dependent S-nitrosylation mediate the cardioinhibition of the antihypertensive catestatin. Am J Physiol Heart Circ Physiol. 2012; 302: 431-442.
12. O'Connor DT, Kailasam MT, Kennedy BP, Ziegler MG, Yanaihara N, Parmer RJ. The catecholamine re-lease-inhibitory "catestatin" region of chromogranin a: early decline in humans at genetic risk of hypertension. Ann N Y Acad Sci. 2002; 971: 533-535. PMID: 12438176
13. O 'Connor DT, Zhu G, Rao F, Taupenot L, Fung MM, Das M, et al. Heritability and genome-wide linkage in US and australian twins identify novel genomic regions controlling chromogranin a: implications for secretion and blood pressure. Circulation. 2008; 118: 247-257. doi: 10.1161/CIRCULATIONAHA.107. 709105 PMID: 18591442
14. Mahapatra NR, O'Connor DT, Vaingankar SM, Sinha Hikim AP, Mahata M, Ray S, et al. Hypertension from targeted ablation of chromogranin A can be rescued by the human ortholog. J Clin Invest. 2005; 115: 1942-1952. PMID: 16007257
15. Dev NB, Gayen JR, O'Connor DT, Mahata SK. Chromogranin a and the autonomic system: decomposition of heart rate variability and rescue by its catestatin fragment. Endocrinology. 2010; 151: 2760-2768. doi: 10.1210/en.2009-1110 PMID: 20410203
16. Biswas N, Curello E, O'Connor DT, Mahata SK. Chromogranin/secretogranin proteins in murine heart: myocardial production of chromogranin A fragment catestatin (Chga(364-384)). Cell Tissue Res. 2010; 342: 353-361. doi: 10.1007/s00441-010-1059-4 PMID: 21052719
17. Penna C, Alloatti G, Gallo MP, Cerra MC, Levi R, Tullio F, et al. Catestatin improves post-ischemic left ventricular function and decreases ischemia/reperfusion injury in heart. Cell Mol Neurobiol. 2010; 30: 1171-1179. doi: 10.1007/s10571-010-9598-5 PMID: 21104119
18. Perrelli MG, Tullio F, Angotti C, Cerra MC, Angelone T, Tota B, et al. Catestatin Reduces Myocardial Ischaemia/ Reperfusion Injury: Involvement of PI3K/Akt, PKCs, Mitochondrial KATP Channels and ROS Signalling. Pflugers Archiv. 2013; 465: 1031-1040. doi: 10.1007/s00424-013-1217-0 PMID: 23319164
19. Brar BK, Helgeland E, Mahata SK, Zhang K, O'Connor DT, Helle KB, et al. Human catestatin peptides differentially regulate infarct size in the ischemic-reperfused rat heart. Regul Pept. 2010; 165: 63-70. doi: 10.1016/j.regpep.2010.07.153 PMID: 20655339
20. Ramella R, Boero O, Alloatti G, Angelone T, Levi R, Gallo MP. Vasostatin 1 activates eNOS in endothelial cells through a proteoglycan-dependent mechanism. J Cell Biochem. 2010; 110: 70-79. doi: 10. 1002/jcb.22510 PMID: 20213742
21. Cerra MC, Gallo MP, Angelone T, Quintieri AM, Pulerà E, Filice E, et al. The homologous rat chromogranin A1-64 (rCGA1-64) modulates myocardial and coronary function in rat heart to counteract adrenergic stimulation indirectly via endothelium-derived nitric oxide. FASEB J. 2008; 22: 3992-4004. doi: 10.1096/fj.08-110239 PMID: 18697842
22. O'Connor DT, Kailasam MT, Kennedy BP, Ziegler MG, Yanaihara N, Parmer RJ. Early decline in the catecholamine release-inhibitory peptide catestatin in humans at genetic risk of hypertension. J Hypertens. 2002; 20: 1335-1345. PMID: 12131530
23. Reers M, Smith TW, Chen LB. J-aggregate formation of a carbocyanine as a quantitative fluorescent indicator of membrane potential. Biochemistry. 1991; 30: 4480-4486. PMID: 2021638
24. Heusch G, Boengler K, Schulz R. Cardioprotection: nitric oxide, protein kinases, and mitochondria. Circulation. 2008; 118: 1915-1919. doi: 10.1161/CIRCULATIONAHA.108.805242 PMID: 18981312
25. Murphy E, Steenbergen C. Does inhibition of glycogen synthase kinase protect in mice? Circ Res. 2008; 103: 226-228. doi: 10.1161/CIRCRESAHA.108.181602 PMID: 18669927
26. Cohen MV, Downey JM. Is it time to translate ischemic preconditioning's mechanism of cardioprotection into clinical practice? J Cardiovasc Pharmacol Ther. 2011; 16: 273-280. doi: 10.1177/ 1074248411407071 PMID: 21821528
27. Hausenloy DJ, Yellon DM. The therapeutic potential of ischemic conditioning: an update. Nat Rev Cardiol. 2011; 8: 619-629. doi: 10.1038/nrcardio.2011.85 PMID: 21691310
28. Theurl M, Schgoer W, Albrecht K, Jeschke J, Egger M, Beer AG, et al. The neuropeptide catestatin acts as a novel angiogenic cytokine via a basic fibroblast growth factor-dependent mechanism. Circ Res. 2010; 107: 1326-1335. doi: 10.1161/CIRCRESAHA.110.219493 PMID: 20930149
29. Wang P, Zweier JL. Measurement of nitric oxide and peroxynitrite generation in the postischemic heart. J Biol Chem. 1996; 271: 29223-29230. PMID: 8910581
30. Juhaszova M, Zorov DB, Kim SH, Pepe S, Fu Q, Fishbein KW, et al. Glycogen synthase kinase-3β mediates convergence of protection signaling to inhibit the mitochondrial permeability transition pore. J Clin Invest. 2004; 113: 1535-1549. PMID: 15173880
31. Ruiz-Meana M, Abellán A, Miró-Casas E, Agulló E, Garcia-Dorado D. Role of sarcoplasmic reticulum in mitochondrial permeability transition and cardiomyocyte death during reperfusion. Am J Physiol Heart Circ Physiol. 2009; 297: 1281-1289. doi: 10.1152/ajpheart.00435.2009 PMID: 19684187
32. Perrelli MG, Pagliaro P, Penna C. Ischemia/reperfusion injury and cardioprotective mechanisms: Role of mitochondria and reactive oxygen species. C World J Cardiol. 2011; 3: 186-200.
33. DeSantiago J, Maier LS, Bers DM. Phospholamban is required for CaMKII-dependent recovery of Ca transients and SR Ca reuptake during acidosis in cardiac myocytes. J Mol Cell Cardiol. 2004; 36: 67-74. PMID: 14734049
34. Xie Y, Zhu Y, Zhong WZ, Chen L, Zhou ZN, Yuan WJ. Role of dual-site phospholamban phosphorylation in intermittent hypoxia-induced cardioprotection against ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol. 2005; 288: 2594-2602.
35. 2+ cycling by direct phosphorylation of phospholamban at Thr17. J Biol Chem. 2009; 284: 28180-28187. doi: 10.1074/jbc.M109.036566 PMID: 19696029